Macugen Patent Expiration

Macugen is a drug owned by Bausch And Lomb Inc. It is protected by 5 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 04, 2017. Details of Macugen's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6011020 Nucleic acid ligand complexes
Jan, 2017

(7 years ago)

Expired
US5932462 Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
Aug, 2016

(8 years ago)

Expired
US6051698 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
May, 2015

(9 years ago)

Expired
US6113906 Water-soluble non-antigenic polymer linkable to biologically active material
Oct, 2013

(11 years ago)

Expired
US5919455 Non-antigenic branched polymer conjugates
Oct, 2013

(11 years ago)

Expired


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Macugen and ongoing litigations to help you estimate the early arrival of Macugen generic.

Macugen's Litigations

Macugen been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 05, 2006, against patent number US6113906. The petitioner , challenged the validity of this patent, with RICHARD B. GREENWALD et al as the respondent. Click below to track the latest information on how companies are challenging Macugen's patents.

Last updated on December 10, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6113906 October, 2006 Decision
(05 Oct, 2006)
RICHARD B. GREENWALD et al

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Macugen is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Macugen's family patents as well as insights into ongoing legal events on those patents.

Macugen's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Macugen's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 04, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Macugen Generics:

There are no approved generic versions for Macugen as of now.





About Macugen

Macugen is a drug owned by Bausch And Lomb Inc. It is used for treating VEGF-mediated ocular diseases. Macugen uses Pegaptanib Sodium as an active ingredient. Macugen was launched by Bausch And Lomb Inc in 2004.

Approval Date:

Macugen was approved by FDA for market use on 17 December, 2004.

Active Ingredient:

Macugen uses Pegaptanib Sodium as the active ingredient. Check out other Drugs and Companies using Pegaptanib Sodium ingredient

Treatment:

Macugen is used for treating VEGF-mediated ocular diseases.

Dosage:

Macugen is available in injectable form for intravitreal use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 0.3MG ACID/0.09ML INJECTABLE Discontinued INTRAVITREAL